Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 1.67
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and...
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only
Buy
Sell